Author: admin

“Actinic Keratosis Market”

(Albany, USA) DelveInsight’s “Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Actinic Keratosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Actinic Keratosis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Actinic Keratosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Actinic Keratosis market.

Request for a Free Sample Report @ Actinic Keratosis Market Forecast

Some facts of the Actinic Keratosis Market Report are:

• According to DelveInsight, Actinic Keratosis market size is expected to grow at a decent CAGR by 2034.
• Leading Actinic Keratosis companies working in the market are VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma CorporationGlaukos Corporation, Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Services, Inc., Microsurgical technology, Molteno Ophthalmic Ltd. ,New World Medical , Santen Pharmaceutical, Sight Scientific, Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, Alimera Sciences, Annexin Pharmaceuticals, Amgen Inc., Cangene Corporation, BD and Bosch Healthcare Solutions GmbH among others.
• Key Actinic Keratosis Therapies expected to launch in the market are AVX001, VDA-1102, and others.
• In February 2025, Almirall, S.A announced results of a Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis
• In November 2024, Vidac Pharma has secured €600,000 ($645,651) in additional funding to advance the clinical development of its two lead cancer candidates. Announced during the company’s recent shareholder meeting, this funding from existing investors will allow Vidac to initiate a new Phase IIb trial for its lead candidate, VDA-1102 (tuvatexib) ointment. The hexokinase 2 inhibitor is being studied for its potential in treating advanced cases of actinic keratosis, a skin condition that may progress to cutaneous squamous cell carcinoma (SCC).
• In May 2024, TORQUR announced results of a Randomized Phase 2 Proof-of-Concept Study to Evaluate the Efficacy and Safety of Topical Bimiralisib Application in Participants Suffering From Actinic Keratosis on the Face and/or Scalp and/or Back of Hands Over a 2 and 4-week Treatment Period
• Additionally, the launch of new therapies such as VDA-1102, SR-T100 Gel, and other innovative topical treatments is anticipated to enhance treatment outcomes and broaden market prospects.
• According to Chetty P et al., the prevalence of AK varies from 6–60%, depending on age, phototype and other predisposing risk factors (most notably immunosuppressed status, outdoor workers), and is increasing
• In a study conducted by Schaefer et al., it was found that the standardized prevalence of AK from dermatological examinations was 2.7%; the rate increased with age (11.5% in the group 60-70 years) and was higher for men (3.9%) than for women (1.5%)

Actinic Keratosis Overview

Actinic keratosis (AK) is a common skin condition characterized by rough, scaly patches that develop due to long-term exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Actinic keratosis usually occurs on areas of the body that receive the most sun exposure, such as the face, scalp, ears, neck, and hands.

These lesions are usually small, red, or flesh-colored, with a rough texture resembling sandpaper. While actinic keratosis is not cancerous in itself, it is considered a precancerous condition, as a small percentage of Actinic keratosis may progress to squamous cell carcinoma, a type of skin cancer.

It is important to have Actinic keratosis evaluated and treated by a healthcare professional. Treatment options include topical creams, cryotherapy (freezing), chemical peels, photodynamic therapy, or surgical removal. Prevention is crucial, and measures such as sun protection (using sunscreen, wearing protective clothing, and seeking shade), regular skin examinations, and avoiding artificial UV radiation can help reduce the risk of developing actinic keratosis. Early detection and treatment of Actinic keratosis can significantly lower the risk of skin cancer.

Learn more about Actinic Keratosis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Actinic Keratosis Treatment Market

Actinic Keratosis Market

The Actinic Keratosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Actinic Keratosis market trends by analyzing the impact of current Actinic Keratosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Actinic Keratosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Actinic Keratosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Actinic Keratosis market in 7MM is expected to witness a major change in the study period 2020-2034.

Actinic Keratosis Epidemiology

The Actinic Keratosis epidemiology section provides insights into the historical and current Actinic Keratosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Actinic Keratosis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Actinic Keratosis Epidemiology @ Actinic Keratosis Prevalence

Actinic Keratosis Drugs Uptake

This section focuses on the uptake rate of the potential Actinic Keratosis drugs recently launched in the Actinic Keratosis market or expected to be launched in 2020-2034. The analysis covers the Actinic Keratosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Actinic Keratosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Actinic Keratosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Actinic Keratosis Pipeline Development Activities

The Actinic Keratosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Actinic Keratosis key players involved in developing targeted therapeutics.

Learn more about the emerging Actinic Keratosis Market drivers and barriers @ Actinic Keratosis Market Dynamics

Actinic Keratosis Therapeutics Assessment

Major key companies are working proactively in the Actinic Keratosis Therapeutics market to develop novel therapies which will drive the Actinic Keratosis treatment markets in the upcoming years are VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma CorporationGlaukos Corporation, Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Services, Inc., Microsurgical technology, Molteno Ophthalmic Ltd. ,New World Medical , Santen Pharmaceutical, Sight Scientific, Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, Alimera Sciences, Annexin Pharmaceuticals, Amgen Inc., Cangene Corporation, BD and Bosch Healthcare Solutions GmbH among others.

Learn more about the emerging Actinic Keratosis therapies & key companies @ Actinic Keratosis Therapies and Companies

Actinic Keratosis Report Key Insights

1. Actinic Keratosis Patient Population

2. Actinic Keratosis Market Size and Trends

3. Key Cross Competition in the Actinic Keratosis Market

4. Actinic Keratosis Market Dynamics (Key Drivers and Barriers)

5. Actinic Keratosis Market Opportunities

6. Actinic Keratosis Therapeutic Approaches

7. Actinic Keratosis Pipeline Analysis

8. Actinic Keratosis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Actinic Keratosis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Actinic Keratosis Competitive Intelligence Analysis

4. Actinic Keratosis Market Overview at a Glance

5. Actinic Keratosis Disease Background and Overview

6. Actinic Keratosis Patient Journey

7. Actinic Keratosis Epidemiology and Patient Population

8. Actinic Keratosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Actinic Keratosis Unmet Needs

10. Key Endpoints of Actinic Keratosis Treatment

11. Actinic Keratosis Marketed Products

12. Actinic Keratosis Emerging Therapies

13. Actinic Keratosis Seven Major Market Analysis

14. Attribute Analysis

15. Actinic Keratosis Market Outlook (7 major markets)

16. Actinic Keratosis Access and Reimbursement Overview

17. KOL Views on the Actinic Keratosis Market

18. Actinic Keratosis Market Drivers

19. Actinic Keratosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Actinic Keratosis Market Forecast 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Treatment, Medication, Therapies, and Companies by DelveInsight

“Alopecia Drugs Market”

(Albany, USA) DelveInsight’s “Alopecia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Alopecia, historical and forecasted epidemiology as well as the Alopecia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Alopecia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Alopecia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Alopecia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Alopecia market.

Request for a Free Sample Report @ Alopecia Market Forecast

Some facts of the Alopecia Market Report are:

• According to DelveInsight, Alopecia market size is expected to grow at a decent CAGR by 2032.
• Leading Alopecia companies working in the market are Aclaris Therapeutics Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc., HCell Inc., Merck & Co. Inc., Sun Pharmaceuticals Industries Ltd, Cipla, Dr. Reddy’s Laboratories Ltd, Viviscal, Histogen, Follica Inc., Kythera Biopharmaceuticals Inc., Regaine, Ranbaxy Laboratories Ltd, Kirkland Signature, Lexington International LLC, Vitabiotics, Alpecin – Dr. Kurt Wolff GmbH & Co, Johnson and Johnson, and GlaxoSmithKline PLC.
• Some of the major driving factors for the Alopecia market are the rising incidence of hair loss, technological innovations in alopecia diagnosis, and the increase in the number of chronic diseases associated with hair loss. Changing lifestyles, such as excessive alcohol and tobacco consumption, and rising stress indices among people, are thought to be major contributors to the rise in the prevalence of alopecia.
• In July 2023, REVIAN Inc. announced that the Revian Red Hair Growth System is expected to be in a second study. It is anticipated as an effective treatment option for Central Centrifugal Cicatricial Alopecia (“CCCA”).
• In June 2023, Pfizer Inc. announced the approval of LITFULO by the U.S. FDA. It is the first treatment that is approved and used for adolescents (12+) to treat severe alopecia areata.
• In January 2023, Sun Pharmaceuticals Industries Ltd announced the acquisition of Concert Pharmaceuticals. The latter is a biotechnology company specializing in treating alopecia areata

Alopecia Overview

Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body. Typically, at least the head is involved, and the severity of hair loss can vary from a small area to the entire body.

About one-third of women experience hair loss at some time in their lives; among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it is less socially acceptable for them. Alopecia can severely affect a woman’s emotional well-being and quality of life.

The condition occurs when white blood cells attack the cells in hair follicles, causing them to shrink and dramatically slow down hair production. It is unknown precisely what causes the body’s immune system to target hair follicles in this way.

There are different types of alopecia varying in terms of causes, severity (how much hair falls out), patterns of hair loss, the usual age it starts and body parts affected. Most of the people have alopecia areata, which is often used as an umbrella name for a spectrum (a range) of types: areata, totalis, and universalis. Because alopecia areata is a spectrum, many people had hair loss ‘in-between’ these named points. Some people found that their alopecia changed along the spectrum over time.

The extreme forms of alopecia areata are alopecia total is, which involves the loss of all head hair, and alopecia universal is, which involves the loss of all hair from the head and the body.

The main type of hair loss in women is the same as it is men.

It is called androgenetic alopecia (AGA), or female (or male) pattern hair loss. In men, hair loss usually begins above the temples, and the receding hairline eventually forms a characteristic “M” shape; hair at the top of the head also thins, often progressing to baldness. In women, androgenetic alopecia begins with gradual thinning at the part line, followed by increasing diffuse hair loss radiating from the top of the head. A woman’s hairline rarely recedes, and women rarely become bald.

Dihydrotestosterone (DHT) is the main hormone responsible for Androgenetic Alopecia in genetically susceptible individuals. DHT causes hair loss by inducing a change in the hair follicles. The hairs produced by the follicles affected by DHT become progressively smaller until eventually the follicles shrink completely and stop producing hair entirely.

Learn more about Alopecia Treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/alopecia-market

Alopecia Market

The Alopecia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Alopecia market trends by analyzing the impact of current Alopecia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Alopecia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alopecia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Alopecia market in 7MM is expected to witness a major change in the study period 2019-2032.

Alopecia Epidemiology

The Alopecia epidemiology section provides insights into the historical and current Alopecia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Alopecia market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Alopecia Epidemiology @ Alopecia Prevalence

Alopecia Drugs Uptake

This section focuses on the uptake rate of the potential Alopecia drugs recently launched in the Alopecia market or expected to be launched in 2019-2032. The analysis covers the Alopecia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Alopecia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Alopecia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alopecia Pipeline Development Activities

The Alopecia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Alopecia key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Alopecia pipeline development activities @ Alopecia Companies and Therapies

Alopecia Therapeutics Assessment

Major key companies are working proactively in the Alopecia Therapeutics market to develop novel therapies which will drive the Alopecia treatment markets in the upcoming years are Aclaris Therapeutics Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc., HCell Inc., Merck & Co. Inc., Sun Pharmaceuticals Industries Ltd, Cipla, Dr. Reddy’s Laboratories Ltd, Viviscal, Histogen, Follica Inc., Kythera Biopharmaceuticals Inc., Regaine, Ranbaxy Laboratories Ltd, Kirkland Signature, Lexington International LLC, Vitabiotics, Alpecin – Dr. Kurt Wolff GmbH & Co, Johnson and Johnson, and GlaxoSmithKline PLC.

Learn more about the emerging Alopecia therapies & key companies @ hAlopecia Clinical Trials and Advancements

Alopecia Report Key Insights

1. Alopecia Patient Population

2. Alopecia Market Size and Trends

3. Key Cross Competition in the Alopecia Market

4. Alopecia Market Dynamics (Key Drivers and Barriers)

5. Alopecia Market Opportunities

6. Alopecia Therapeutic Approaches

7. Alopecia Pipeline Analysis

8. Alopecia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Alopecia Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Alopecia Competitive Intelligence Analysis

4. Alopecia Market Overview at a Glance

5. Alopecia Disease Background and Overview

6. Alopecia Patient Journey

7. Alopecia Epidemiology and Patient Population

8. Alopecia Treatment Algorithm, Current Treatment, and Medical Practices

9. Alopecia Unmet Needs

10. Key Endpoints of Alopecia Treatment

11. Alopecia Marketed Products

12. Alopecia Emerging Therapies

13. Alopecia Seven Major Market Analysis

14. Attribute Analysis

15. Alopecia Market Outlook (7 major markets)

16. Alopecia Access and Reimbursement Overview

17. KOL Views on the Alopecia Market

18. Alopecia Market Drivers

19. Alopecia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alopecia Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, NDA Approval, Revenue, Statistics, MOA, Therapies, Companies by DelveInsight

“Acne Vulgaris Treatment Market”

(Albany, USA) DelveInsight’s comprehensive report titled “Acne Vulgaris Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of acne vulgaris. The report presents historical and projected epidemiological data covering Total Prevalent Cases of Acne Vulgaris, Total Diagnosed Prevalent Cases of Acne vulgaris, Gender specific Diagnosed Prevalent Cases of Acne Vulgaris and Severity-Specific Diagnosed prevalent Cases of Acne Vulgaris.

The Acne Vulgaris market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Acne Vulgaris market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Acne Vulgaris treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Acne Vulgaris market.

Explore the intricate details of the Acne Vulgaris Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Acne Vulgaris Market Forecast. Click here to stay ahead in healthcare innovation @ Acne Vulgaris Market Size

Key Takeaways from the Acne Vulgaris Market Report

• The Acne Vulgaris Market Size in the 7MM was approximately USD 4,256 million in 2023.
• In 2023, the Acne Vulgaris Market Size was highest in the US among the 7MM, accounting for approximately USD 2,949 million which is further expected to increase by 2034.
• In December 2024:- UCB Biopharma SRL- A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa. The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
• In December 2024:- Incyte Corporation- The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
• June 2024:- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.- A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Efficacy and Safety of Clascoterone Cream 1% in Treatment of Subjects With Facial Acne Vulgaris. The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
• June 2024:- Sanofi- A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age
• June 2024:- AbbVie- An International, Multicenter, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars.
• June 2024:- UCB Biopharma SRL- A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa.
• June 2024:- Incyte Corporation- A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa. The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
• As per the analysis, in Japan, the prevalence of acne vulgaris among the students was 58.6%, with the average onset at 13.3 years of age.
• The evaluation of acne severity revealed that “mild acne” was the most common form across all subgroups, affecting 92% of adult females, 82% of adult males, 89% of teenage females, and 77% of teenage males, in Italy.
• In a survey of employees in Germany, the overall prevalence of acne was found to be 4.2%. Other studies indicate that the prevalence of acne in adolescents aged 9 to 20 can reach up to 95%, without distinguishing between clinical and “physiologic” acne.
• The leading Acne Vulgaris Companies such as Ortho Dermatologics, Bausch Health, Galderma Labs, Timber Pharmaceuticals, BioPharmX, Kintor Pharma, Botanix Pharmaceuticals, Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation and others
• Promising Acne Vulgaris Therapies such as Anifrolumab, CFZ533, Bimekizumab, Povorcitinib Clascoterone, DMT310, Winlevi (clascoterone) 1% & Duac gel, Erythromycin 4% topical gel formulation, ASC40, and others.

Delve deep into the Acne Vulgaris Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Acne Vulgaris Market Forecast. Click here to shape the future @ Acne Vulgaris Epidemiology Insights

Acne Vulgaris Overview

Acne vulgaris is a common, chronic skin condition that occurs when hair follicles become clogged with oil, dead skin cells, and bacteria, leading to inflammation. It primarily affects adolescents and young adults but can persist into adulthood. The condition is influenced by multiple factors, including hormonal changes, excess sebum production, bacterial overgrowth (Cutibacterium acnes), genetics, and lifestyle factors.

Acne presents in various forms, including whiteheads, blackheads, papules, pustules, nodules, and cysts. It most commonly appears on the face, chest, shoulders, and back. While mild cases may resolve with over-the-counter treatments, moderate to severe acne often requires prescription medications such as topical retinoids, benzoyl peroxide, antibiotics, or oral treatments like isotretinoin and hormonal therapies.

Early treatment is essential to prevent scarring, post-inflammatory hyperpigmentation, and psychological distress, as acne can significantly impact self-esteem and quality of life. Dermatological advancements, including laser therapy and targeted biologics, are expanding treatment options. Lifestyle modifications, such as a balanced diet, proper skincare, and stress management, can also aid in acne control. While acne is not life-threatening, its social and emotional impact makes it a critical area of ongoing research and innovation in dermatology.

Acne Vulgaris Epidemiology Insights

• Total Prevalent Cases
• Total Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalent Cases
• Severity-specific Diagnosed Prevalent Cases
• Treated Cases

Navigate the complexities of the Acne Vulgaris Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Acne Vulgaris Market Forecast. Click here to get more insights @ Acne Vulgaris Treatment Market

Acne Vulgaris Drug Market

According to DelveInsight’s estimates, the Acne Vulgaris market size in the 7MM is expected to show positive growth, during the forecast period (2024–2034), mainly attributed to the increasing prevalence of acne vulgaris, growing awareness and diagnoses, and the new product launches. The expected increase in treated cases of acne vulgaris in the US is driven by factors such as improved awareness, advancements in treatment options, changing lifestyles, and evolving societal attitudes towards skincare and self-care. These factors collectively contribute to a greater demand for acne treatment and management services. Furthermore these cases are subjected to change during the forecast period (2024-2034).

Acne Vulgaris Treatment Landscape

Acne treatment depends on the individual’s age and sex, the extent and severity of the acne, the period since it has been present, and response to previous treatments. Treatment for mild acne includes topical anti-acne preparations, lasers and lights. Treatment for moderate acne includes antibiotics such as tetracyclines and/or antiandrogens such as birth controlpills. Treatment for severe acne may require a course of oral isotretinoin. Azelaic acid is a naturally occurring acid produced by yeast. It has antibacterial properties. A 20% azelaic acid cream or gel seems to be as effective as many conventional acne treatments when used twice a day.

Acne Vulgaris Market Insights

Several treatments are available for acne vulgaris, there is a need for more effective long-term maintenance therapies to prevent acne recurrence and minimize the risk of scarring. Some individuals with acne vulgaris may not respond adequately to existing treatments, including antibiotics, topical retinoids, and hormonal therapies. There is a need for alternative treatment options for these resistant cases. Many acne treatments, particularly oral medications like isotretinoin, can have significant side effects. There is a need for therapies that effectively treat acne while minimizing adverse effects, especially in adolescents and young adults. Acne vulgaris is a heterogeneous condition, and treatment efficacy can vary greatly among individuals. There is a need for personalized treatment approaches that take into account factors such as acne severity, skin type, hormonal status, and potential comorbidities.

Unlock insights into the Acne Vulgaris Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Acne Vulgaris Market Forecast. Click here @ Acne Vulgaris Market Drivers and Barriers

Marketed Acne Vulgaris Drugs

• AKLIEF: Galderma Labs

AKLIEF (trifarotene) Cream, 0.005%, is indicated for the topical treatment of acne. It selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin, making it the first topical retinoid to do so. Trifarotene is the first new retinoid molecule to receive US FDA approval for acne treatment in over 20 years. AKLIEF Cream is specifically studied and proven to treat both facial (forehead, cheeks, nose, and chin) and truncal (chest, shoulders, and back) acne, providing healthcare professionals and acne patients with an additional treatment option.

• ARAZLO: Ortho Dermatologics/Bausch Health

ARAZLO (tazarotene) Lotion, 0.045%, is a prescription medication used topically to treat acne in individuals aged 9 years and older. It effectively addresses various acne symptoms, including blackheads, whiteheads, and other types of pimples. Notably, ARAZLO is the first tazarotene acne treatment available in lotion form, offering strong efficacy coupled with favorable tolerability.

• CABTREO: Ortho Dermatologics/Bausch Health

CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1% is a prescription medication specifically designed for topical use on the skin to treat acne vulgaris in adults and children aged 12 years and older. It is the first and only FDA-approved fixed-dose, triple-combination topical treatment for acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide to effectively address acne symptoms.

Emerging Acne Vulgaris Drugs

The acne vulgaris Drug Market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including BioPharmX, Kintor Pharma, Botanix Pharmaceuticals, and others, have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.

• BPX-01: Timber Pharmaceuticals/BioPharmX

BPX-01 (topical minocycline, 2%) is being developed for the treatment of moderate-to-severe acne. In a Phase 2b study, treatment with BPX-01 showed a statistically significant reduction in the number of acne lesions, with no serious adverse events related to study treatment. BPX-01 is a hydrophilic topical gel with fully solubilized minocycline capable of penetrating the skin to deliver the antibiotic to where acne develops in the pilosebaceous unit. Currently, the drug is in Phase II of clinical development for the treatment of acne.

• KX-826: Kintor Pharma

KX-826 is being developed by Kintor Pharmaceuticals, for Acne vulgaris. This agent targets mild to moderate patients and is being developed in topical formulation. The company is looking forward to the next step of filing IND to initiate the clinical development of the drug.

• BTX 1503: Botanix Pharmaceuticals

Botanix Pharmaceuticals is advancing BTX 1503, a novel topical treatment designed for moderate to severe acne. This formulation harnesses synthetic cannabidiol as the active drug component, in conjunction with Botanix’s proprietary Permetrex drug delivery technology. Notably, the company has released Phase II results and is now preparing for Phase III clinical trials for the treatment of acne.

Scope of the Acne Vulgaris Market Report

• Coverage- 7MM
• Acne Vulgaris Companies- Ortho Dermatologics, Bausch Health, Galderma Labs, Timber Pharmaceuticals, BioPharmX, Kintor Pharma, Botanix Pharmaceuticals, Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation and others
• Acne Vulgaris Therapies- Clascoterone, DMT310, Winlevi (clascoterone) 1% & Duac gel, Erythromycin 4% topical gel formulation, ASC40, and others.
• Acne Vulgaris Market Dynamics: Acne Vulgaris Market drivers and Exocrine Pancreatic Insufficiency Market Barriers
• Acne Vulgaris Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Acne Vulgaris Unmet Needs, KOL’s views, Analyst’s views, Acne Vulgaris Market Access and Reimbursement

Gain a strategic edge in the Acne Vulgaris Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Acne Vulgaris Market Forecast. Click here to lead in advancements @ Acne Vulgaris Clinical Trials and Therapeutic Assessment

Table of Content

1 Key Insights

2 Report Introduction

3 Acne Vulgaris Market Overview at a Glance

4 Epidemiology and Market Methodology

5 Executive Summary

6 Acne Vulgaris Key Events

7 Disease Background and Overview: Acne Vulgaris

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Therapies

11 Emerging Therapies

12 Acne Vulgaris: Seven Major Market Analysis

13 Key Opinion Leaders’ Views

14 Unmet Needs

15 SWOT Analysis

16 Acne Vulgaris Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acne Vulgaris Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Medication, Therapies, and Companies by DelveInsight

“Pemphigus Vulgaris Market”

(Albany, USA) DelveInsight’s “Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Pemphigus Vulgaris market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Pemphigus Vulgaris market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Pemphigus Vulgaris treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Pemphigus Vulgaris market.

To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast

Some of the key facts of the Pemphigus Vulgaris Market Report:

• The Pemphigus Vulgaris market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• The United States Pemphigus Vulgaris Market accounted for approximately USD 250 million in 2023.
• In January 2025, Cabaletta Bio announced results of a Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris
• In September 2024, IRIS Research and Development, LLC announced results of an Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
• In August 2024, Treatment has begun for the first patient in an investigator-initiated basket trial (IIT) evaluating AlloNK® in combination with rituximab for conditions including rheumatoid arthritis, pemphigus vulgaris, granulomatosis with polyangiitis/microscopic polyangiitis, and systemic lupus erythematosus (SLE). This trial is being conducted by Integral Rheumatology & Immunology Specialists (IRIS), a community rheumatology clinic, highlighting the potential to provide AlloNK® to patients in community settings as well as in academic and transplant centers. The study aims to assess the safety, tolerability, and clinical efficacy of AlloNK® (also referred to as AB-101).
• Among the 7MM, the United States accounted for the highest number of cases of Pemphigus Vulgaris in 2023, with nearly 40,000 cases. These cases are anticipated to increase by 2034.
• The projections indicate the highest diagnosed prevalence of Pemphigus Vulgaris in the United States, with an estimated around 14,000 cases in the year 2022.
• Among the entire diagnosed population of nearly 14,000 Pemphigus Vulgaris cases in the United States, the highest incidence was identified in the age group of 60–69 years, while the lowest cases were observed in the 0–17 years age group in the year 2022.
• Pemphigus Vulgaris projections indicate that within the entire diagnosed prevalent population of Pemphigus Vulgaris in the US in 2022, around 6,000 cases were categorized as mild, 4,000 as moderate, and 4,300 accounted for severe cases.
• Within the EU4 and the UK, Germany reported the highest diagnosed prevalent population of Pemphigus Vulgaris, totaling around 8,000 cases, followed by the United Kingdom. In contrast, France had the lowest diagnosed prevalent population, with approximately 3,000 cases in 2022.
• Key Pemphigus Vulgaris Companies: Roche, Cabaletta Bio, Principia Biopharma, Genentech, Inc., Kemia, Inc, argenx Rho Federal Systems Division, Inc, and others
• Key Pemphigus Vulgaris Therapies: PRN1008, Mycophenolate Mofetil, KC706, efgartigimod PH20 SC, Moderna mRNA-1273, and others
• The Pemphigus Vulgaris epidemiology based on gender analyzed that a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2020–2034)
• The Pemphigus Vulgaris market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pemphigus Vulgaris pipeline products will significantly revolutionize the Pemphigus Vulgaris market dynamics.

Pemphigus Vulgaris Overview

Pemphigus vulgaris (PV) is a rare, chronic autoimmune blistering disorder affecting the skin and mucous membranes. It occurs when the immune system mistakenly produces autoantibodies against desmogleins, key proteins responsible for cell adhesion in the epidermis. This leads to the loss of cohesion between skin cells, causing fragile blisters and painful erosions.

Pemphigus vulgaris primarily affects middle-aged and older adults, with symptoms often beginning in the mouth before spreading to other parts of the body. The blisters are flaccid, rupture easily, and leave raw, painful sores that can increase the risk of infections and complications.

Pemphigus vulgaris Diagnosis is confirmed through clinical examination, skin biopsy, direct immunofluorescence, and serological tests detecting autoantibodies. Treatment mainly involves systemic corticosteroids and immunosuppressants, such as azathioprine, mycophenolate mofetil, or rituximab, to control the immune response. Advances in biologic therapies have improved disease management and reduced reliance on long-term steroid use.

While Pemphigus vulgaris is potentially life-threatening if left untreated, early diagnosis and proper treatment significantly improve outcomes. Long-term monitoring is essential to prevent relapses and manage side effects of immunosuppressive therapy. Ongoing research aims to develop targeted therapies to improve disease control with fewer adverse effects.

Get a Free sample for the Pemphigus Vulgaris Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market

Pemphigus Vulgaris Market Drivers and Barriers

The Pemphigus Vulgaris (PV) market is driven by increasing awareness, advancements in biologic therapies, and a rising prevalence of autoimmune disorders. The growing adoption of targeted therapies, such as rituximab, has significantly improved patient outcomes, reducing dependence on long-term corticosteroids and minimizing side effects. Additionally, ongoing research and development efforts, along with regulatory approvals for novel immunotherapies, are expanding treatment options. However, the market faces barriers such as the high cost of biologic drugs, limited availability of treatment in certain regions, and challenges in early diagnosis due to the rarity of the disease. The long-term use of immunosuppressive therapies also raises concerns regarding adverse effects, infections, and patient compliance. Furthermore, the small patient population poses a challenge for pharmaceutical companies in conducting large-scale clinical trials and achieving widespread commercial success. Despite these obstacles, increasing research investments and improved healthcare access are expected to drive market growth.

Pemphigus Vulgaris Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pemphigus Vulgaris Epidemiology Segmentation:

The Pemphigus Vulgaris market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Pemphigus Vulgaris
• Prevalent Cases of Pemphigus Vulgaris by severity
• Gender-specific Prevalence of Pemphigus Vulgaris
• Diagnosed Cases of Episodic and Chronic Pemphigus Vulgaris

Download the report to understand which factors are driving Pemphigus Vulgaris epidemiology trends @ Pemphigus Vulgaris Epidemiology Forecast

Pemphigus Vulgaris Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pemphigus Vulgaris market or expected to get launched during the study period. The analysis covers Pemphigus Vulgaris market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pemphigus Vulgaris Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pemphigus Vulgaris Therapies and Key Companies

• PRN1008: Principia Biopharma
• Mycophenolate Mofetil: Genentech, Inc.
• KC706: Kemia, Inc
• efgartigimod PH20 SC: argenx
• Moderna mRNA-1273: Rho Federal Systems Division, Inc

Discover more about therapies set to grab major Pemphigus Vulgaris market share @ Pemphigus Vulgaris Treatment Landscape

Scope of the Pemphigus Vulgaris Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Pemphigus Vulgaris Companies: Roche, Cabaletta Bio, Principia Biopharma, Genentech, Inc., Kemia, Inc, argenx Rho Federal Systems Division, Inc, and others

• Key Pemphigus Vulgaris Therapies: PRN1008, Mycophenolate Mofetil, KC706, efgartigimod PH20 SC, Moderna mRNA-1273, and others
• Pemphigus Vulgaris Therapeutic Assessment: Pemphigus Vulgaris current marketed and Pemphigus Vulgaris emerging therapies
• Pemphigus Vulgaris Market Dynamics: Pemphigus Vulgaris market drivers and Pemphigus Vulgaris market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Pemphigus Vulgaris Unmet Needs, KOL’s views, Analyst’s views, Pemphigus Vulgaris Market Access and Reimbursement

To know more about Pemphigus Vulgaris companies working in the treatment market, visit @ Pemphigus Vulgaris Clinical Trials and Therapeutic Assessment

Table of Contents

1. Pemphigus Vulgaris Market Report Introduction

2. Executive Summary for Pemphigus Vulgaris

3. SWOT analysis of Pemphigus Vulgaris

4. Pemphigus Vulgaris Patient Share (%) Overview at a Glance

5. Pemphigus Vulgaris Market Overview at a Glance

6. Pemphigus Vulgaris Disease Background and Overview

7. Pemphigus Vulgaris Epidemiology and Patient Population

8. Country-Specific Patient Population of Pemphigus Vulgaris

9. Pemphigus Vulgaris Current Treatment and Medical Practices

10. Pemphigus Vulgaris Unmet Needs

11. Pemphigus Vulgaris Emerging Therapies

12. Pemphigus Vulgaris Market Outlook

13. Country-Wise Pemphigus Vulgaris Market Analysis (2020–2034)

14. Pemphigus Vulgaris Market Access and Reimbursement of Therapies

15. Pemphigus Vulgaris Market Drivers

16. Pemphigus Vulgaris Market Barriers

17. Pemphigus Vulgaris Appendix

18. Pemphigus Vulgaris Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pemphigus Vulgaris Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, NDA Approval, Revenue, Statistics, MOA, Therapies, Companies by DelveInsight